[Press News] New Strategic Partnership to Advance Intelligent Organ-on-Chip Technology in Drug Development!

Molecular Devices and Anivance AI Corporation Announce Strategic Partnership to Advance Intelligent Organ-on-Chip Technology in Drug Development

Taipei, November 7, 2024 — 

Molecular Devices, a global leader in life science technologies, and Anivance AI Corporation today announced the signing of a strategic cooperation agreement. Together, they aim to advance the application of intelligent organ-on-chip technology in the biopharmaceutical market, accelerating drug development processes.

This collaboration combines expertise in 3D cell culture, high-throughput screening, and organ-on-chip technologies. The goal is to create drug development processes that better mimic human physiological responses, thus improving drug screening efficiency and data analysis. Molecular Devices believes this partnership will expand their capabilities in the Asian market, particularly enhancing high-throughput imaging and data processing to shorten development cycles and increase the success rate of new drugs.

Anivance AI's Bio-AI chip technology has achieved breakthroughs in simulating physiological systems, including respiratory models, liver targeting, and tumor microenvironments. These advances offer high-precision and high-throughput solutions, significantly reducing the reliance on animal testing in drug development. The cooperation between Molecular Devices and Anivance AI is expected to further strengthen high-throughput analysis and data processing capabilities, accelerating the translation of research into real-world outcomes.

To support alternative testing methods and foster scientific innovation, Anivance AI has launched the "R&D Support Program" in line with global 3R trends and Taiwan's "Chip Innovation Plan." This program provides standardized, all-in-one services, covering experimental design and testing services, allowing researchers to focus on innovation. It also integrates Anivance AI's proprietary ResearchGPT, a secure AI system for imaging data analysis, academic search, and real-time meeting transcription, enhancing team collaboration and streamlining research workflows.

Since its launch in October, more than 50 clinical and industry professionals have engaged with the program, showcasing the market's strong demand for such solutions. One participant noted, "The R&D Support Program has provided substantial assistance in drug development and data analysis, accelerating our research timeline."

As a core brand of the Danaher Life Sciences platform, Molecular Devices has long focused on providing integrated hardware and software solutions for areas including microplate analysis, 3D cell culture, high-efficiency drug screening, and cell line development. Their automated, intelligent solutions have enhanced experimental throughput and reproducibility, aiding scientists in accelerating discoveries and improving quality of life.

Molecular Devices has consistently supported clients in academia, pharma, government, and biotech to drive scientific breakthroughs, enabling early diagnosis and safer therapies. The company is optimistic about the next decade's potential for biochip and organoid technologies, particularly in Asia. Through this world-class collaboration, Molecular Devices aims to help emerging companies overcome bottlenecks in workflows, intelligence, and automation, building a future-focused life sciences laboratory that meets global and local research needs.

This strategic partnership symbolizes the deep integration of cutting-edge technology and pharmaceutical innovation, marking a transformation in drug development models that better align with human physiological responses. It will inject new energy into the biopharmaceutical industry and usher in a new era of medical innovation.